Respicardia
OverviewSuggest Edit
Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
| Type | Private | |
| Founded | 2006 | |
| HQ | Hopkins, US | Map |
| Website | respicardia.com |
Latest Updates
| Employees (est.) (Oct 2020) | 73 | (+2%) |
| Cybersecurity rating | C | More |
Key People/Management at Respicardia
B. Kristine Johnson
Director
Peter Sommerness
President and CEO, Director
Tim Hauch
Chief Financial Officer
Kirk Nielsen
Director
Robin Germany
Chief Medical Officer
Jonathan A. Rennert
Director
Respicardia Office Locations
Respicardia has an office in Hopkins
Hopkins, US (HQ)
12400 Whitewater Dr #150
Respicardia Financials and Metrics
Summary Metrics
Founding Date | 2006 |
Respicardia total Funding | $149.1 m |
Respicardia latest funding size | $58.50 m |
Time since last funding | 3 years ago |
Respicardia investors | Polaris Partners, Versant Ventures, Three Arch Partners, Accuitive Medical Ventures, Affinity Capital Management, RK Ventures Group, Sorin Group, Polaris Venture Capital, Abbott, ZOLL Medical Corporation |
Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Respicardia Cybersecurity Score
Respicardia Online and Social Media Presence
Respicardia's Trends
Respicardia News and Updates
August 06, 2018
CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea
MINNETONKA, Minn., Aug. 6, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) ...
Respicardia Blogs
July 11, 2019
Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea
Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced the publication of the 24- and 36-month data from the remedē® System Pivotal Trial in the peer-reviewed journal SLEEP....
May 30, 2019
Therapy Update: Implanted Neurostimulators for Sleep Apnea
By Sree Roy, Sleep Review Magazine
Inspire Medical, Respicardia, LivaNova, and Nyxoah share the latest data on their devices.
May 30, 2019
The Valley Hospital Introduces Sleep Apnea Advance
The Valley Hospital is one of only two sites in New Jersey and the tri-state area currently using a new implantable device to treat adult patients with central sleep apnea. Central sleep apnea is a serious condition in which a person’s sleep is interrupted...
May 30, 2019
Device delivers sleep apnea relief for retired NASA engineer
By Greg Sullivan
Al Harbury is no stranger to innovation. He worked for Lockheed Martin and later as an aerospace system engineer with NASA’s Ames Research Center in California, before retiring to North Carolina. But a little more than a year ago, the 87-year-old Clemmons, North Carolina man bega…
May 30, 2019
UCHealth first in region to offer latest technology for central sleep apnea
By: Kelly Tracer, UCHealth
LOVELAND, Colo. (April 4, 2019) – UCHealth is the first health system in the Rocky Mountain region to offer the latest, implantable treatment option for people with central sleep apnea. In a recent breakthrough procedure at UCHealth Medical Center of the Rockies in Lovela…
November 06, 2018
CMS Grants Outpatient Pass-through Payment to the remedē® System for the Treatment of Central Sleep Apnea
Pass-through Payment to Provide Additional Medicare Reimbursement for the remedē System
Respicardia Frequently Asked Questions
When was Respicardia founded?
Respicardia was founded in 2006.
Who are Respicardia key executives?
Respicardia's key executives are B. Kristine Johnson, Peter Sommerness and Tim Hauch.
How many employees does Respicardia have?
Respicardia has 73 employees.
Who are Respicardia competitors?
Competitors of Respicardia include Novian Health, Obalon Therapeutics and VisCardia.
Where is Respicardia headquarters?
Respicardia headquarters is located at 12400 Whitewater Dr #150, Hopkins.
Where are Respicardia offices?
Respicardia has an office in Hopkins.
How many offices does Respicardia have?
Respicardia has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies